Article published online: 2023-05-08
J. Fetal Med. (June 2016) 3:55–61
DOI 10.1007/s40556-016-0087-x
REVIEW ARTICLE
Prediction of Pre-eclampsia
Kanwal Gujral1 • Sakshi Nayar2
Received: 28 December 2015 / Accepted: 13 April 2016 / Published online: 27 May 2016
Society of Fetal Medicine 2016
Abstract Pre-eclampsia (PE) is a disease of high maternal,
fetal, and neonatal mortality and morbidity. Early recognition, ideally in the first trimester of women at risk for PE
will enable prophylaxis and help reduce associated adverse
outcomes. No single test is supported by robust evidence to
predict PE and no single test has emerged as a front runner.
Screening based on risk factors has low sensitivity. Uterine
artery Doppler is the primary screening modality for prediction of PE. Individually, no biomarker has shown to
have sufficient clinical value in prediction of PE. However,
sFlt-1/PlGF ratio performs better than others. A combination of uterine artery Doppler, maternal serum biomarkers,
and maternal characteristics offers best predictive power at
the moment.
Keywords Pre-eclampsia Prediction of pre-eclampsia
Screening of pre-eclampsia
Introduction
The incidence of pre-eclampsia (PE) and eclampsia is 4.6
and 1.6 %, respectively with an overall incidence of 10 %
for all hypertensive disorders of pregnancy [1, 2]. Preeclampsia is subdivided into early onset and late onset type,
the former diagnosed and needing delivery before 34 weeks
and the later after 34 weeks. Overall, 10–15 % of direct
& Kanwal Gujral
kgg_in@yahoo.com
1
Institute of Obstetrics and Gynaecology, Sir Ganga Ram
Hospital, Rajinder Nagar, New Delhi 110060, India
2
Department of Obstetrics and Gynaecology, Lady Hardinge
Medical College & Smt. S. K. Hospital, New Delhi, India
maternal deaths are associated with PE and eclampsia [2].
PE is also a major cause of fetal, neonatal mortality, and
morbidity worldwide. It is, therefore, not surprising that
intense research is on to predict and thus prevent PE.
Pathophysiology
The disease is illusive. Whatsoever the trigger may be
genetic, immunological, or environmental, the basic pathophysiology, as understood today, is a ‘defective placentation’, which means failure of trophoblasts to migrate, invade
the spiral arterioles, and convert them into wide flaccid
channels from narrow contractile ones. When this remodeling is incomplete, there is an increase in resistance to blood
flow in the uterine arteries as reflected by measurement of
uterine artery Doppler. Because of reduced uteroplacental
perfusion and resultant ischemia, there is release of various
biochemical analytes, which can be measured in the
maternal serum. These resulting ischemic products cause
multiorgan dysfunction. Early onset PE is due to defective
placentation, whereas late onset PE is because of aging of
normal placenta or/and increased maternal predisposition.
Prediction
World Health Organization (WHO) in 2004, while
reviewing all existing tests for prediction of PE, laid down
the criteria for a good prediction test that the test should be
simple, rapid, noninvasive, inexpensive, easy to carry out,
early in gestation, impose minimal discomfort or risk,
widely available, valid, reliable, and reproducible with high
likelihood ratio (LR) for a positive result ([10), and low
likelihood ratio for a negative result (\0.1). WHO further
concluded that none of the existing tests meet these criteria
[3]. The various screening modalities are discussed below.
123
56
J. Fetal Med. (June 2016) 3:55–61
Screening Based on Risk Factors
Traditionally, screening or prediction of PE has been based
on risk factors (Table 1) [4].
Uterine Artery Doppler during First Trimester
and Prediction of PE
Table 1 Risk factors for prediction of PE and relative risk
Risk factors for PE
Relative risk
Nulliparity
3
Prior PE
7
Advanced maternal age
2
Chronic hypertension
–
Chronic renal disease
Diabetes
–
3.5
Obesity
–
Multiple gestation
3
Vascular/Connective tissue disorder(e.g., lupus)
–
Antiphospholipid antibody syndrome/Thrombophilia
9
Family history of PE
2–4
Patient born SGA
–
Prior adverse pregnancy outcomes
–
Poon et al. [5] showed that screening tool based on risk
factors carries a detection rate of 37 % for early PE,
28.9 % for late PE, and 20.7 % for gestational hypertension (GH) at a false positive rate of 5 %.
The first prospective study correlating abnormal uterine
artery Doppler waveforms and PE was published by Harrington et al. in 1997 [6]. Following this landmark study,
many studies have been published with a wide range of
prediction and use of different criteria (Table 2).
Inference from these studies is that prediction accuracy is
greater for early onset PE than for late onset PE and accuracy
increases when maternal history and risk factors are included.
A very recent large meta-analysis by Velauthar on
55,974 women firmly established that uterine artery Doppler during first trimester is a useful tool for prediction of
PE (sensitivity 47.8 %, specificity 92.1 % for early onset
PE; sensitivity 26.4 %, specificity 93.4 % for any PE). The
numbers needed to treat (NNT) with aspirin to prevent one
case of early onset PE fell from 1000 to 173 and from 2500
PE pre-eclamsia SGA small for gestational age
Table 2 Uterine artery Doppler velocimetry during first trimester and the prediction of PE
Author, year
Prevalence of PE
Doppler criteria
Sensiti-
Specifi-
vity (%)
city (%)
PPV (%) NPV (%)
Martin, 2001 [7]
63/3045 (2.1 %)
Mean PI>2.35
27
95.4
11
98.4
Martin, 2001 [7]
14/3045 (0.46 %)
Mean PI>2.35
50
95.1
4.5
99.8
22/999 (2.2 %)
Mean PI>95th
24
95.1
11.3
97.9
48.5
91.8
6.2
99.4
90.9
90
6
99.9
40.8
90
8.7
98.4
81.1
90
3.1
99.9
45.3
90
10.1
99
Early PE
Gomez, 2005 [8]
centile
Melchiorre,
90/3058 (2.9 %)
Plasencia, 2008
Mean UtA-RI>90th
centile
2008 [9]
22/3107 (0.71 %)
Mean PI>95th
centile + history
[10]
Early PE
Plasencia, 2008
71/3107 (2.3 %)
Mean PI>95th
centile + history
[10]
Late PE
Poon, 2009 [11]
37/8366 (0.44 %)
Early PE
Poon, 2009 [11]
Late PE
Lowest UtA-PI
MOM+ history
128/8366 (1.5 %)
Lowest UtA-PI
MOM + history
MOM multiples of the median, NPV negative predictive value, PI pulsatility index, PPV positive predictive value, UtA uterine artery
123
J. Fetal Med. (June 2016) 3:55–61
57
Table 3 Uterine artery Doppler velocimetry during second trimester and the prediction of PE
Author, Year
Doppler criteria
Sensitivity
Steele, 1990
RI > 0.58
63 % all PE
North, 1994
RI > 90th percentile
27 % all PE
[14]
Notch 27%
Albaiges,
Bilateral notching
35 %
2000 [15]
PI > 95th percentile
80 % early onset PE
Yu, 2008
PI > 95th percentile
77 % early onset PE
[13]
[16]
all PE
21.9 % late onset PE
Onwudiwe,
MAP Maternal
100 % early onset PE
2008 [17]
history
56.4 % late onset PE
PI > 95th percentile
Cnossen,
Review of 74 studies
Low -risk women
2008 [18]
80,000 women
Sens. 23 %, Sp. 99 % over all
↑ PI, notch
Sens. 78 % Sp. 95 % severe PE
High-risk women
Sens. 19 %, Sp. 99 % over all
Sens. 80 %, Sp. 78 % severe PE
MAP mean arterial pressure, PE pre-eclampsia, PI pulsatility index, RI resistance index
to 421 for a background risk varying between 1 and 0.4 %,
respectively. The authors conclude that based on NNT,
abnormal uterine artery Doppler in low-risk women
achieves a sufficiently high performance to justify aspirin
prophylaxis in those who test positive [12].
Uterine Artery Doppler during Second Trimester
and Prediction of PE
Studies on the performance of uterine artery Doppler for
prediction of PE during second trimester are set in Table 3.
Inference from this data is that uterine artery Doppler
during second trimester has the benefit of improved
detection rates as compared to first trimester Doppler, but
may be identifying pregnancies at a point when intervention is no longer effective or possible.
A sequential use of uterine artery Doppler during first
and second trimester suggests that women who have a
relative worsening of mean pulsatility index (PI) from first
to second trimester and those who have persistence of
abnormal PI in second trimester are more likely to develop
PE [19, 20].
On the other hand, many authors do not recommend
routine screening of all women for prediction of PE
because of high false positive rates, health care costs,
besides adding anxiety to patients [3, 21–23].
123
58
J. Fetal Med. (June 2016) 3:55–61
Table 4 Accuracy of seven markers for prediction of PE
Marker
No. of studies
Detection rates
PP13
5
36 – 80 % for early PE
PAPP A
8
22 – 43 % for early PE
PIGF
4
41 – 59 % for early PE, 33 % for late
PE
ADAM 12
5
37 % unspecified PE
Inhibin A
2
35 % unspecified PE
Activin
1
20 % unspecified PE
fβHCG
1
22 % unspecified PE
Maternal Serum Biochemical Markers
for Prediction of PE
A host of biomarkers have been linked to the development
of PE
; PAPP –A, ; PP13, ; PlGF, ; VEGF, ; ADAM12, ;
AFP
: Inhibin A, : Activin A, : fbHCG, : sFlt, : IMA, :
NGAL, : Cystatin C, : PTX3
: urinary kallikerin, altered PlGF sFlt ratio, and : cell
free fetal DNA
Sylwia Kuc et al. [24] undertook a systematic review
of published literature to assess the accuracy of seven
common biomarkers for prediction of PE. Table 4 depicts
their observations on the studies for each biomarker with
detection rates at a fixed false positive rate (FPR) of
10 %.
Recently, a lot of work has been done on angiogenic
markers (PlGF) which are decreased and antiangiogenic
markers (SFlt and SEng), which are increased in women
who are destined to develop PE. Also, there is a plausible
hypothesis that an imbalance between the two that is, an
altered ratio can predict PE with greater accuracy. Findings
of a large systematic review of 22 case control and 12
cohort studies—on PlGF, sEng, and sFlt-1 are presented
below [25]:
• PlGF ò
Diag OR 9.0 (95 % CI 5.6–14.5) FPR 5 %
• sFlt-1 æ
Diag OR 6.6 (95 % CI 3.1–13.7) FPR 5 %
Sensitivity 26 %
• sEng æ
Diag OR 4.2 (95 % CI 2.4–7.2) FPR 5 %
Sensitivity 18 %
Women with Suspicion of PE or PE Already
Confirmed
• \38—rules out PE irrespective of GA for one week
• [85 (early onset PE 20–33.6 weeks), [110 (late onset
PE C 34 weeks)—likely to have PE, re-measure after
2–4 days
• 38–85 (early onset PE), 38–110 (late onset PE)—
moderate or high risk for developing PE in four weeks,
follow in 1–2 weeks early onset PE, lower threshold for
induction of labor (IOL) for late onset PE
• Already confirmed PE
[ 655 at\34 þ 0 weeks Need to deliver
[ 201 at 34 þ 0 weeks
Asymptomatic Women at High Risk of PE
•
•
•
•
History or abnormal UtA Doppler
Normal ratio (\38)—rules out PE for at least one week
Serial measurements can be considered
Optimal time to start is 24–26 weeks because at this
time, the difference in values between women with
normal outcome and those destined to develop early PE
are usually already significant.
However, the authors caution that as of today, Sflt, PlGF,
or Sflt/PlGF ratio has not been incorporated into any official guideline.
WHO global program to conquer PE has undertaken a
large prospective observational study with the aim to
measure sFlt1, sEng, VEGF, and PlGF levels longitudinally in blood and urine in about 8000 high- and low-risk
women. Result of this study will perhaps establish the role
of biochemical markers for prediction of PE.
Sensitivity 32 %
The authors conclude that although concentrations of these
markers before 30 weeks were predictive of PE, most of these
markers did not perform well in the first half of pregnancy.
123
Verlohren et al. have listed the studies on the performance of sFlt-1/PlGF ratio in the diagnosis and prediction
of PE (Table 5) [26].
The above mentioned data demonstrate that the sFlt-1/
PlGF ratio has the best detection rate for prediction of PE
amongst all biomarkers, but how to utilize it in clinical
practice, what are the alert cut-offs, and how often to repeat
remain the core issues.
Stephan et al. in their opinion statement in 2015 have suggested that sFlt-1/PlGF ratio has become an additional tool for
predicting as well as managing PE in the following manner [27].
Combination of Maternal Characteristics, Uterine
Artery Doppler, and Serum Biomarkers
In order to improve upon detection rates, several
investigators have combined different biomarkers along
with maternal characteristics and uterine artery Doppler
J. Fetal Med. (June 2016) 3:55–61
59
Table 5 Studies on the performance of sFlt-1/PlGF ratio in the diagnosis and prediction of PE [26]
Study
Number of patients with PE (control)
Patients
Sensitivity (%)
Specificity (%)
I Before onset of PE
Stepan et al. (2007)
12 (38)
9 (38)
All patients
62
51
Early-onset PE
67
51
Kim et al. (2007)
46 (100)
All patients
80.4
78
Crispi et al. (2008)
38 (76)
Early-onset PE
84.2
90
Diab et al. (2008)
33 (108)
8 (108)
All PEs
100
85
Early-onset PE
90
90
De Vivo et al. (2008)
52 (52)
All patients
88.5
88.5
Kusanovic et al. (2009)
62 (1560)
All patients
40.3
78.5
37 (268)
34 (268)
Early-onset PE
Late-onset PE
89
74
97
89
71 (268)
All patients
82
95
15 (144)
Early-onset PE
100
95
19 (144)
Late-onset PE
95
95
34 (144)
All patients
97
95
II During PE
Verlohren et al. (2010)
Ohkuchi et al. (2010)
Sunderji et al. (2010)
39 (388)
9 (1613)
in first trimester [24, 28–32] as well as in second trimester [32–34].
Giguere et al. while assessing 37 studies utilizing 71
different combinations have highlighted that in low-risk
population PP13, PAPP-A, ADAM 12, activin A, or
inhibin A in first or early second trimester and uterine
artery Doppler in second trimester has a sensitivity of
60–80 % and specificity of [80 %, whereas in high-risk
population PP13, uterine artery PI in first trimester has a
sensitivity of 90 % and specificity of 90 % (result of a
single study) [35].
A model for prediction of PE was developed by Poon
et al. in 2009. The model incorporated maternal characteristics (BMI, nulliparity, previous h/o PE, ethnic origin),
uterine artery Doppler, maternal MAP, PAPP-A, and PlGF.
It was tested on 7797 women with singleton pregnancies in
their first trimester. The results were impressive—for early
PE, the sensitivity was 94.1 %, and specificity was 94.3 %
at a FPR of 5 %. The positive likelihood ratio (LR) was
16.5 and negative LR was 0.06, easily meeting the WHO
criteria [3]. Predictive result for late PE and GH were
35.7 % and 18.3 %, respectively. Overall, one in five
women who were screen positive, developed hypertensive
disease of pregnancy [36]. This model so far has the best
predictive power but has not been replicated in any other
study.
In nutshell, predictive efficacy of multiple markers for
prediction of PE has been evaluated on a large scale as
All patients
96
97
Early-onset PE
100
89.1
discussed in the article, but utilization in clinical practice
for an individual patient and offering preventive strategies, like aspirin, metformin, anticoagulation, etc. is the
key to overcome PE related maternal and fetal morbidities and mortality. The model of personalized risk
prediction and prevention given by Baschat et al. [37] is
perhaps the answer (Fig. 1). The model incorporates
maternal risk factors (personal, placental, cardiovascular,
metabolic, and prothrombotic) along with first trimester
screening, and offering preventive modalities accordingly. The logic behind this is that women with these
risk factors are more prone to develop PE. These findings are echoed in a study by Scholten et al. [38] where
they evaluated 1297 formerly pre-eclamptic women
6–12 months postpartum for these risk profiles. Cardiovascular risk factors were seen in 66.1 % hyperhomocysteinemia in 18.7 %, metabolic syndrome in 15.5 %,
and thrombophilia in 12.8 %. Overall, 77 % of women
had at least one risk factor.
Indian data on prediction of PE is scant. Studies from
year 2000 onwards have linked low calcium, creatinine
ratio [39, 40], low superoxide dismutase, catalase, RBC
glutathione, vitamin E [41], high midtrimester b-hcg [42],
positive microalbuminuria [43], and isometric handgrip test
to the development of PE [44]. These new markers have
not been studied in the Indian population, but the potential
is enormous for a nation of 1.32 billion with a birth rate of
22.22/1000 population.
123
60
J. Fetal Med. (June 2016) 3:55–61
Fig. 1 Model of personalized risk prediction and prevention [37]
Conclusion
Pre-eclampsia remains an important cause of maternal/fetal
mortality and morbidity. Prediction of PE is a challenging
task. Individually, no test is supported by robust evidence
to predict PE. A combination of uterine artery Doppler,
maternal serum analytes, and maternal characteristics
offers best predictive approach at the moment.
Compliance with Ethical Standards
Conflict of interest None.
References
1. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and
regional estimates of preeclampsia and eclampsia: a systematic
review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1–7.
2. Duley L. The global impact of pre-eclampsia and eclampsia.
Semin Perinatol. 2009;33(3):130–7.
3. Conde-Agudelo A, Villar J, Lindheimer M. World Health
Organization systematic review of screening tests for
preeclampsia. Obstet Gynecol. 2004;104(6):1367–91.
4. Duckitt K, Harrington D. Risk factors for pre-eclampsia at
antenatal booking: systematic review of controlled studies. BMJ.
2005;330(7491):565.
5. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH.
Maternal risk factors for hypertensive disorders in pregnancy: a
multivariate approach. J Hum Hypertens. 2010;24(2):104–10.
123
6. Harrington K, Goldfrad C, Carpenter RG, Campbell S.
Transvaginal uterine and umbilical artery Doppler examination of
12–16 weeks and the subsequent development of pre-eclampsia
and intrauterine growth retardation. Ultrasound Obstet Gynecol.
1997;9:94–100.
7. Martin AM, Bindra R, Curcio P. Screening for pre- eclampsia and
fetal growth restriction by uterine artery Doppler at 11-14 weeks
of gestation. Ultrasound Obstet Gynecol. 2001;18:583–6.
8. Gomez O, Martinez JM, Figueras F. Uterine artery Doppler at
11-14 weeks of gestation to screen for hypertensive disorders and
associated complications in an unselected population. Ultrasound
Obstet Gynecol. 2005;26:490–4.
9. Melchiorre K, Wormald B, Leslie K. First trimester uterine artery
Doppler indicates in term and preterm pre eclampsia. Ultrasound
Obstet Gynecol. 2008;32:133–7.
10. Plasencia W, Maiz N, Poon L. Uterine artery Doppler at 11 ? 0
to 13 ? 6 weeks and 21 ? 0 to 24 ? 6 weeks in the prediction
of pre eclampsia. Ultrasound Obstet Gynecol. 2008;32:138–46.
11. Poon LC, Karagiannis G, Leal A. Hypertensive disorders in
pregnancy: screening by uterine artery Doppler imaging and
blood pressure at 11–13 weeks. Ultrasound Obstet Gynecol.
2009;34:497–502.
12. Velauthar L, Plana MN, Kalidindi M, Zamora J, Thilaganathan B,
Illanes SE, Khan KS, Aquilina J, Thangaratinam S. First-trimester uterine artery Doppler and adverse pregnancy outcome: a
meta-analysis involving 55,974 women. Ultrasound Obstet
Gynecol. 2014;43(5):500–7.
13. Steele SA, Pearce JM, McParland P, Chamberlain GV. Early
Doppler ultrasound screening in prediction of hypertensive disorders of pregnancy. Lancet. 1990;335(8705):1548–51.
14. North RA, Ferrier C, Long D, Townend K, Kincaid-Smith P.
Uterine artery Doppler flow velocity waveforms in the second
trimester for the prediction of preeclampsia and fetal growth
retardation. Obstet Gynecol. 1994;83(3):378–86.
J. Fetal Med. (June 2016) 3:55–61
15. Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides
KH. One-stage screening for pregnancy complications by color
Doppler assessment of the uterine arteries at 23 weeks’ gestation.
Obstet Gynecol. 2000;96(4):559–64.
16. Yu CK, Khouri O, Onwudiwe N, Spiliopoulos Y, Nicolaides KH.
Prediction of pre-eclampsia by uterine artery Doppler imaging:
relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol. 2008;31(3):310–3.
17. Onwudiwe N, Yu CK, Poon LC, Spiliopoulos I, Nicolaides KH.
Prediction of pre-eclampsia by a combination of maternal history,
uterine artery Doppler and mean arterial pressure. Ultrasound
Obstet Gynecol. 2008;32(7):877–83.
18. Cnossen JS, Morris RK, ter Riet G. Use of uterine artery Doppler
ultrasonography to predict pre-eclampsia and intra uterine growth
restriction: a systematic review and bivariable meta-analysis.
CMAJ. 2008;178:701–11.
19. Plasencia W, Maiz N, Poon L, Yu C, Nicolaides KH. Uterine
artery Doppler at 11 ? 0 to 13 ? 6 weeks and 21 ? 0 to
24 ? 6 weeks in the prediction of pre-eclampsia. Ultrasound
Obstet Gynecol. 2008;32(2):138–46.
20. Herraiz I, Escribano D, Gómez-Arriaga PI, Hernı́ndez-Garcı́a JM,
Herraiz MA, Galindo A. Predictive value of sequential models of
uterine artery Doppler in pregnancies at high risk for preeclampsia. Ultrasound Obstet Gynecol. 2012;40(1):68–74.
21. Papageorghiou AT, Yu CK, Nicolaides KH. The role of uterine
artery Doppler in predicting adverse pregnancy outcome. Best
Pract Res Clin Obstet Gynaecol. 2004;18(3):383–96.
22. Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH.
An integrated model for the prediction of preeclampsia using
maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol. 2005;193(2):429–36.
23. Myatt L, Clifton RG, Roberts JM, et al. The utility of uterine
artery Doppler velocimetry in prediction of preeclampsia in a
low-risk population. Obstet Gynecol. 2012;120:815–22.
24. Kuc S, Esther JW, Bas BV, Arie F, Gerard HA, Peter CJ. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first trimester prediction of pre-eclampsia: a systematic
review. Obstet Gynecol Survey. 2011;66(4):225–39.
25. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM,
van der Post JA, von Dadelszen P, Mol BW, Pajkrt E. Accuracy
of circulating placental growth factor, vascular endothelial
growth factor, soluble fms-like tyrosine kinase 1 and soluble
endoglin in the prediction of pre-eclampsia: a systematic review
and meta-analysis. BJOG. 2012;119(7):778–87.
26. Verlohren S, Stepan H, Dechend R. Angiogenic growth factors in
the diagnosis and prediction of pre-eclampsia. Clin Sci (Lond).
2012;122(2):43–52.
27. Stepan H, Herraiz I, Schlembach D, Verlohren S, Brennecke S,
Chantraine F, Klein E, Lapaire O, Llurba E, Ramoni A, Vatish M,
Wertaschnigg D, Galindo A. Implementation of the sFlt-1/PlGF
ratio for prediction and diagnosis of pre-eclampsia in singleton
pregnancy: implications for clinical practice. Ultrasound Obstet
Gynecol. 2015;45(3):241–6.
28. Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M,
Meiri H, Tal J, Cuckle HS. A novel approach to first-trimester
screening for early pre-eclampsia combining serum PP-13 and
Dopplerultrasound. Ultrasound Obstet Gynecol. 2006;27(1):13–7.
29. Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH.
Maternal serum placental growth factor at 11 ? 0 to
61
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
13 ? 6 weeks of gestation in the prediction of pre-eclampsia.
Ultrasound Obstet Gynecol. 2008;32(6):732–9.
Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides
KH. Maternal plasma inhibin A at 11–13 weeks of gestation in
hypertensive disorders of pregnancy. Prenat Diagn. 2009;29(8):
753–60.
Pilalis A, Souka AP, Antsaklis P, Daskalakis G, Papantoniou N,
Mesogitis S, Antsaklis A. Screening for pre-eclampsia and fetal
growth restriction by uterine artery Doppler and PAPP-A at
11–14 weeks’ gestation. Ultrasound Obstet Gynecol. 2007;29(2):
135–40.
Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH.
Prediction of pregnancy complications by first-trimester maternal
serum PAPP-A and free beta-hCG and with second-trimester
uterine artery Doppler. Prenat Diagn. 2005;25(10):949–53.
Spencer K, Cowans NJ, Chefetz I, Tal J, Kuhnreich I, Meiri H.
Second-trimester uterine artery Doppler pulsatility index and
maternal serum PP13 as markers of pre-eclampsia. Prenat Diagn.
2007;27(3):258–63.
Crispi F, Llurba E, Domı́nguez C, Martı́n-Gallán P, Cabero L,
Gratacós E. Predictive value of angiogenic factors and uterine
artery Doppler for early- versus late-onset pre-eclampsia and
intrauterine growth restriction. Ultrasound Obstet Gynecol.
2008;31(3):303–9.
Giguere Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, Lafond J, Legare F, Forest JC. Combining biochemical
and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem. 2010;56(3):361–75.
Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH.
First-trimester prediction of hypertensive disorders in pregnancy.
Hypertension. 2009;53(5):812–8.
Baschat AA. First-trimester screening for pre-eclampsia: moving
from personalized risk prediction to prevention. Ultrasound
Obstet Gynecol. 2015;45(2):119–29.
Scholten RR, Hopman MT, Sweep FC, Van de Vlugt MJ, Van
Dijk AP, Oyen WJ, Lotgering FK, Spaanderman ME. Co-occurrence of cardiovascular and prothrombotic risk factors in
women with a history of preeclampsia. Obstet Gynecol.
2013;121(1):97–105.
Desai P, Malik S. Serum urinary calcium: creatinine ration in
predicting pregnancy induced hypertension. How useful? J Obstet
Gynecol India. 2001;51(4):61–3.
Kar J, Shrivastava K, Mishra RK. Role of urinary calcium creatinine ratio in prediction of pregnancy induced hypertension.
J Obstet Gynecol India. 2002;52(2):39–41.
Ananda S, Shanmugsunderam RK. Antioxidant enzymes in erythrocytes and placenta of preeclampsia. J Obstet Gynecol India.
2001;51(4):50–1.
Desai P, Rao S. Predictive values of raised mid trimester Betahcg in pregnancy included hypertension. J Obstet Gynecol India.
2002;52(1):68–70.
Chhabra S, Gandhi D. Prediction of PIH/PET by detecting
microalbuminuria in mid trimester. J Obstet Gynecol India.
2001;52(1):56–7.
Kaur D, Saini AS, Kaur A. Evaluation of isometric exercise
(hand-grip test) as a predictor of PIH. J Obstet Gyencol India.
2003;53:115–7.
123